Want to see SE:MCAP full AI Analyst Report?
MCAP Stock Chart & Stats
kr533.00
-kr4.00(-1.07%)
At close: 4:00 PM EST
kr533.00
-kr4.00(-1.07%)
Day’s Range― - ―
52-Week Rangekr440.00 - kr677.00
Previous CloseN/A
Volume7.13K
Average Volume (3M)21.82K
Market Cap
kr7.67B
Enterprise Valuekr7.30B
Total Cash (Recent Filing)kr394.40M
Total Debt (Recent Filing)kr478.10M
Price to Earnings (P/E)33.3
Beta0.66
Next Earnings
Jul 21, 2026EPS Estimate
4.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.01
Shares Outstanding15,080,753
10 Day Avg. Volume14,106
30 Day Avg. Volume21,821
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.61
Revenue Forecast (FY)kr2.33B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthVery high reported TTM revenue (~SEK 2.17B, ~+298% YoY) reflects material scale-up from acquisitions and organic expansion. A larger, growing revenue base supports cross-selling, procurement leverage and reinvestment capacity, underpinning durable growth over months.
ProfitabilityHealthy EBIT (~15.3%) and net margins (~10.4%) indicate persistent earnings power across the portfolio. Sustained margins point to pricing power and operational discipline within med-tech subsidiaries, supporting long-term cash generation and value creation.
Cash GenerationSolid TTM operating cash (~SEK 339M) and FCF (~SEK 295M) demonstrate the group's ability to convert earnings into spendable cash. Reliable cashflow supports add-on acquisitions, capex and debt servicing, bolstering the buy-and-build strategy over the medium term.
Bears Say
Gross Margin VolatilityLarge swings in gross margin suggest material variability from cost mix, potential one-offs or classification changes. Such volatility undermines earnings predictability, complicates integration of acquisitions and makes pricing and margin improvement initiatives harder to plan reliably.
Rising LeverageMeaningful increase in debt and leverage reduces financial flexibility and raises refinancing risk. Higher leverage can increase interest burdens and limit capacity for further bolt-on acquisitions or cushioning against demand shocks across the portfolio.
Weaker Cash ConversionOCF covering only ~0.69x of EBIT and uneven FCF growth points to working-capital timing or integration drains. Persistent weaker cash conversion can constrain funding for growth, force more external financing, and reduce resilience to operational setbacks.
MedCap AB News
MCAP FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was kr440.00 and its highest was kr677.00 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is kr7.67B.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Jul 21, 2026 which is in 9 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Apr 29, 2026. The company reported kr4.57 earnings per share for the quarter, missing the consensus estimate of kr4.67 by -kr0.1.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 4.74.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,080,753 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of kr4.57 in its last earnings report, missing expectations of kr4.67. Following the earnings report the stock price went up 2.268%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in SE:MCAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---